Drugs / NG01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06961383 | Oct 2025 → Oct 2027 expected | secondary progressive multiple sclerosis | NeuroGenesis Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NG01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06961383 ↗ |
| Modality | Cell therapy | “cellular therapy product” NCT06961383 ↗ |
| Route | Intrathecal | “repeated intrathecal (IT) injection of NG01” NCT06961383 ↗ |